BiotechTube

LY518674

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Metabolic Syndrome X

Conditions

Metabolic Syndrome X

Trial Timeline

Jan 1, 2006 → Nov 1, 2006

NCT ID
NCT00327002

About LY518674

LY518674 is a phase 2 stage product being developed by Eli Lilly for Metabolic Syndrome X. The current trial status is completed. This product is registered under clinical trial identifier NCT00327002. Target conditions include Metabolic Syndrome X.

What happened to similar drugs?

19 of 20 similar drugs in Metabolic Syndrome X were approved

Approved (19) Terminated (4) Active (1)
✅Telmisartan 40mg + Rosuvastatin 20mg + Telmisartan 80mg + Rosuvastatin 20mg + Telmisartan 40mg, 80 mg + Rosuvastatin 20mgYuhanApproved
✅Metformin + PlaceboEli LillyApproved
✅Henagliflozin 10 mg daily + Metformin 1700 mg dailyJiangsu Hengrui MedicineApproved
✅Rosuvastatin + AtorvastatinAstraZenecaApproved
✅rosuvastatinAstraZenecaApproved
✅Simvastatin + Simvastatin/EzetimibeMerckApproved
✅Simvastatin + Vytorin + Placebo + EzetimibeMerckApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00327002Phase 2Completed

Competing Products

20 competing products in Metabolic Syndrome X

See all competitors
ProductCompanyStageHype Score
Telmisartan 40mg + Rosuvastatin 20mg + Telmisartan 80mg + Rosuvastatin 20mg + Telmisartan 40mg, 80 mg + Rosuvastatin 20mgYuhanApproved
35
Olmesartan medoxomil tablets low dose + Olmesartan medoxomil tablets high dose + AmlodipineDaiichi SankyoPhase 3
40
olmesartan medoxomil + placebo + olmesartan medoxomil + olmesartan medoxomilDaiichi SankyoPhase 3
40
14C-labeled YM178Astellas PharmaPhase 1
29
TRC150094Torrent PharmaceuticalsPhase 1/2
32
Tirzepatide + Retatrutide + PlaceboEli LillyPhase 3
47
Metformin + PlaceboEli LillyApproved
43
Tirzepatide + SemaglutideEli LillyPre-clinical
18
LY3849891 + PlaceboEli LillyPhase 1
33
Henagliflozin 10 mg daily + Metformin 1700 mg dailyJiangsu Hengrui MedicineApproved
50
RosuvastatinAstraZenecaPhase 3
40
Rosuvastatin + AtorvastatinAstraZenecaApproved
43
AZD2693 + PlaceboAstraZenecaPhase 1
29
RosuvastatinAstraZenecaPhase 3
40
Rosuvastatin + AtorvastatinAstraZenecaPhase 3
40
rosuvastatinAstraZenecaApproved
43
EfinopegdutideMerckPhase 2
35
MK0767 + Comparator: fenofibrate + Comparator: Placebo (unspecified)MerckPhase 2
27
Vericiguat + PlaceboMerckPhase 2
35
MetforminMerckPhase 2
35